全文获取类型
收费全文 | 20676篇 |
免费 | 2049篇 |
国内免费 | 11篇 |
出版年
2021年 | 244篇 |
2020年 | 147篇 |
2019年 | 229篇 |
2018年 | 221篇 |
2017年 | 201篇 |
2016年 | 383篇 |
2015年 | 698篇 |
2014年 | 741篇 |
2013年 | 965篇 |
2012年 | 1211篇 |
2011年 | 1250篇 |
2010年 | 760篇 |
2009年 | 717篇 |
2008年 | 1067篇 |
2007年 | 1123篇 |
2006年 | 983篇 |
2005年 | 1034篇 |
2004年 | 993篇 |
2003年 | 910篇 |
2002年 | 928篇 |
2001年 | 308篇 |
2000年 | 291篇 |
1999年 | 284篇 |
1998年 | 274篇 |
1997年 | 208篇 |
1996年 | 184篇 |
1995年 | 176篇 |
1994年 | 170篇 |
1993年 | 171篇 |
1992年 | 207篇 |
1991年 | 220篇 |
1990年 | 193篇 |
1989年 | 188篇 |
1988年 | 205篇 |
1987年 | 179篇 |
1986年 | 177篇 |
1985年 | 181篇 |
1984年 | 261篇 |
1983年 | 189篇 |
1982年 | 219篇 |
1981年 | 217篇 |
1980年 | 211篇 |
1979年 | 198篇 |
1978年 | 183篇 |
1977年 | 177篇 |
1976年 | 154篇 |
1975年 | 141篇 |
1974年 | 180篇 |
1973年 | 152篇 |
1969年 | 108篇 |
排序方式: 共有10000条查询结果,搜索用时 691 毫秒
1.
Based on its proven anabolic effects on bone in osteoporosis patients, recombinant parathyroid hormone (PTH1-34) has been evaluated as a potential therapy for skeletal repair. In animals, the effect of PTH1-34 has been investigated in various skeletal repair models such as fractures, allografting, spinal arthrodesis and distraction
osteogenesis. These studies have demonstrated that intermittent PTH1-34 treatment enhances and accelerates the skeletal repair process via a number of mechanisms, which include effects on mesenchymal
stem cells, angiogenesis, chondrogenesis, bone formation and resorption. Furthermore, PTH1-34 has been shown to enhance bone repair in challenged animal models of aging, inflammatory arthritis and glucocorticoid-induced
bone loss. This pre-clinical success has led to off-label clinical use and a number of case reports documenting PTH1-34 treatment of delayed-unions and non-unions have been published. Although a recently completed phase 2 clinical trial of PTH1-34 treatment of patients with radius fracture has failed to achieve its primary outcome, largely because of effective healing
in the placebo group, several secondary outcomes are statistically significant, highlighting important issues concerning the
appropriate patient population for PTH1-34 therapy in skeletal repair. Here, we review our current knowledge of the effects of PTH1-34 therapy for bone healing, enumerate several critical unresolved issues (e.g., appropriate dosing regimen and indications)
and discuss the long-term potential of this drug as an adjuvant for endogenous tissue engineering. 相似文献
2.
3.
4.
Edward Harrison 《BMJ (Clinical research ed.)》1916,1(2888):645-647
5.
Transcriptional regulatory network triggered by oxidative signals configures the early response mechanisms of japonica rice to chilling stress 总被引:3,自引:0,他引:3
6.
7.
J M Allen J P O'Shea K Mashiter G Williams S R Bloom 《BMJ (Clinical research ed.)》1983,286(6378):1607-1609
Ten patients with advanced progressive adenocarcinoma of the prostate were treated with a long acting analogue of gonadotrophin releasing hormone. Eight of these patients responded to treatment in terms of pain relief and clinical regression of tumour. Serum gonadotrophin and testosterone concentrations were significantly suppressed by the end of the second week of treatment, testosterone concentrations being comparable with those achieved by castration. The two patients who failed to respond had both relapsed previously when receiving conventional treatment, and neither showed any endocrine response to the analogue. Superagonists of gonadotrophin releasing hormone may be the treatment of choice in adenocarcinoma of the prostate, but further trials are required to establish long term safety and efficacy. 相似文献
8.
Bruce M. Taylor Ronald W. Sarver Gregory Fici Roger A. Poorman Barry S. Lutzke Antonio Molinari Thomas Kawabe Karl Kappenman Allen E. Buhl Dennis E. Epps 《The protein journal》2003,22(1):31-40
The time dependency of the spontaneous aggregation of the fibrillogenic β-Amyloid peptide, Aβ1–40, was measured by turbidity, circular dichroism, HPLC, and fluorescence polarization. The results by all methods were comparable and they were most consistent with a kinetic model where the peptide first slowly forms an activated monomeric derivative (AM), which is the only species able to initiate, by tetramerization, the formation of linear aggregates. The anti-Aβ antibody 6E10, raised against residues 1–17, at concentrations of 200–300 nM delayed significantly the aggregation of 50 μM amyloid peptide. The anti–Aβ antibody 4G8, raised against residues 17–24, was much less active in that respect, while the antibody A162, raised against the C-terminal residues 39–43 of the full-length Aβ was totally inactive at those concentrations. Concomitant with the aggregation experiments, we also measured the time dependency of the Aβ1–40–induced toxicity toward SH-EP1 cells and hippocampal neurons, evaluated by SYTOX Green fluorescence, lactate dehydrogenase release, and activation of caspases. The extent of cell damage measured by all methods reached a maximum at the same time and this maximum coincided with that of the concentration of AM. According to the kinetic scheme, the latter is the only transient peptide species whose concentration passes through a maximum. Thus, it appears that the toxic species of Aβ1–40 is most likely the same transient activated monomer that is responsible for the nucleation of fibril formation. These conclusions should provide a structural basis for understanding the toxicity of Aβ1–40 in vitro and possibly in vivo. 相似文献
9.
10.